Precision Medicine Group Acquisition, Valuation, Funding & Investors

Precision Medicine Group was acquired by McKesson for $2.3B in August 2026, a 2.4x multiple on $950M of revenue.

Precision Medicine Group acquisition price

$2.3B

Acquired by McKesson · Aug 2026

Precision Medicine Group revenue at acquisition

$950M

Last twelve months · Aug 2026

Precision Medicine Group revenue multiple at acquisition

2.4x

EV/Revenue · Aug 2026

Precision Medicine Group EBITDA multiple at acquisition

16.7x

EV/EBITDA · Aug 2026

Precision Medicine Group Overview

About Precision Medicine Group

Precision Medicine Group is a Bethesda, Maryland-based provider of clinical research and biopharma commercialization services, founded in 2012. The company supports biopharmaceutical companies across drug development and commercialization, including clinical trial management, data analytics, market access, flow cytometry-based immune monitoring, and biospecimen and bioanalytical services, with particular expertise in precision medicine, oncology, and rare diseases. It operates globally across North America, Europe, and Asia with more than 3,500 employees, and its integrated services have supported over $33 billion in client capital raises and $55 billion in M&A activity since 2020.


Founded

2012

HQ

United StatesWashington, DC

Status

Acquired

Customer focus

B2B

Revenue model

Services

Revenue

$950M (Aug 2026)

Valuation

$2.3B (acquired Aug 2026)

Precision Medicine Group Acquisition

Precision Medicine Group was acquired by McKesson for $2.3B on 25 August 2026.

The acquisition price implies a 2.4x revenue and 16.7x EBITDA multiple on $950M of revenue.

Before the acquisition Precision Medicine Group had raised $310M across 2 funding rounds.

McKesson agreed in August 2026 to acquire Precision Medicine Group for approximately $2.25 billion in cash, with the business set to become part of McKesson’s Oncology & Multispecialty segment. The transaction is intended to strengthen McKesson’s higher-growth clinical research and biopharma commercialization services, expanding its capabilities in drug-launch support and oncology-related services. Precision Medicine Group is a global provider of clinical research and biopharma commercialization services. The deal was announced as a definitive agreement and is subject to customary closing conditions, including regulatory approvals. Precision Medicine Group was being acquired from Blackstone.

Precision Medicine Group acquisition details
AcquirerDateTypePriceEV/RevenueEV/EBITDA
25 Aug 2026Strategic M&A$2.3B2.4x16.7x

Precision Medicine Group Funding History

Precision Medicine Group has raised a total of $310M across 2 funding rounds.

Precision Medicine Group's first fundraising round was a $275M undisclosed-stage round in December 2017. The most recent completed round was a $35M undisclosed-stage round in March 2021.

Precision Medicine Group funding rounds

Precision Medicine Group funding rounds
DateStageInvestorsRaisedDeal Summary
Mar 2021Undisclosed stage-$35MPrecision Medicine Group is a Bethesda, Maryland-based company founded in 2012, specializing in services for drug development and commercialization, with over 3,500 employees across North America, Europe, and Asia. It has raised significant funding, including a $275 million investment in December 2017 led by Berkshire Partners and TPG Growth, and a major investment from Blackstone in November 2020 described as Private Equity - IV, with total funding across five rounds amounting to $584.68M from investors like Oak Investment Partners, J.H. Whitney, LCI Capital, and Vida Ventures. A January 2021 acquisition of Project Farma bolstered cell and gene therapy capabilities, enhancing end-to-end services for manufacturing and scale-up of advanced therapies. The company supports over 70% of FDA-approved cell and gene therapies and has facilitated client capital raises of over $33 billion and M&A exceeding $55 billion since 2020 through integrated services.
Dec 2017Undisclosed stageBerkshire Partners (lead); TPG (lead); J.H. Whitney & Co; Oak Investment Partners$275MPrecision Medicine Group (PMG), founded in 2012, is a specialty services company providing diagnostics, drug development, and commercialization solutions for biopharmaceutical and diagnostic companies, including advanced flow cytometry for immune monitoring, global biospecimen collection, bioanalytical services, clinical trials support, and economic value demonstration. The company operates at the intersection of drugs and diagnostics to accelerate development, approval, and commercial success of innovative treatments. On December 19, 2017, PMG announced a $275 million investment led by Berkshire Partners and TPG Growth, with significant participation from co-founders, management, and original investors Oak Investment Partners and J.H. Whitney. This marked Berkshire Partners' first investment in PMG and an expansion of TPG Growth's position from a prior December 2015 investment. Described as a management recapitalization, the funding supports global expansion, with PMG having grown to over 1,000 employees across 22 locations in the U.S., Canada, and Europe at the time. PMG's CEO Mark Clein highlighted the investment as recognition of progress and future potential, while Chairman Ethan Leder noted Berkshire Partners' prior value addition. Investors praised PMG's unique services addressing key industry challenges, with TPG Growth partner Matt Hobart emphasizing its innovative position and Berkshire's Chris Hadley focusing on growth acceleration.

Who has invested in Precision Medicine Group?

4 investors have backed Precision Medicine Group across its funding rounds, including TPG, Oak Investment Partners, Berkshire Partners and J.H. Whitney & Co.

Lead investors include Berkshire Partners and TPG.


Precision Medicine Group Investors

Investors in Precision Medicine Group by funding rounds participated
InvestorHQRoundsRoleFirst check
Berkshire PartnersUnited StatesBoston, MA1LeadDec 2017
J.H. Whitney & CoUnited StatesStamford, CT1ParticipantDec 2017

This data is available for Pro users. Sign up to see all 4 Precision Medicine Group investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Precision Medicine Group

Precision Medicine Group has acquired 3 companies to date.

Last acquisition by Precision Medicine Group was on January 14th 2021. Precision Medicine Group acquired Project Farma for undisclosed valuation.


Latest Acquisitions by Precision Medicine Group

Project Farma
Stern Investor Relations
Epiontis
Description
Project Farma is a Boston-headquartered consulting firm serving pharmaceutical, biotech, and medical device companies. It provides supply chain optimization, regulatory compliance, and operational excellence across manufacturing, distribution, and commercialization stages. Services include FDA audit preparation, serialization implementation, and cold chain validation. The firm advises on Track & Trace systems compliant with DSCSA regulations. Founded in 2012, Project Farma supports clients like Pfizer and Johnson & Johnson, managing projects valued at over $100 million.
Stern Investor Relations is a New York-based consultancy that provides investor relations services exclusively to biotechnology and healthcare companies. The firm crafts communication strategies, organizes investor conferences, and manages relationships with institutional investors and analysts. Stern Investor Relations tracks regulatory changes from the FDA and SEC alongside financial metrics to position clients for capital raises. It serves public companies at various stages, including those in oncology, rare diseases, and medical devices, drawing on expertise from former biotech executives.
Epiontis is a Berlin-headquartered biotech offering epigenetic immune monitoring services since 2003. Located in Adlershof Science Park, the company quantifies cell types like regulatory T cells and tumor-infiltrating lymphocytes using DNA methylation assays. Epiontis supports clinical trials in autoimmune diseases, infections, and cancer with standardized and custom assays.
HQ CountryUnited StatesUnited StatesGermany
HQ City
Dover, DE
New York City, NY
Berlin
Deal Date14 Jan 202119 Dec 20184 Oct 2017
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Precision Medicine Group acquisitions and their M&A valuation multiples.

Start Free Trial

Precision Medicine Group Competitors

Precision Medicine Group competitors include listed companies like Ipsos, Clarivate, GlobalData and Gartner, and private ones like Mu Sigma and Sutherland.

Public and private companies comparable to Precision Medicine Group
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
IpsosFranceFrancePublicly listed$2.9B$429M$1.7B0.7x
Mu SigmaIndiaBangalorePrivate$200M-$1.5B7.5x
ClarivateUnited KingdomUnited KingdomPublicly listed$2.5B$829M$1.2B2.2x
SutherlandUnited StatesRochester, NYPrivate--$1B-
GlobalDataUnited KingdomUnited KingdomPublicly listed$433M$140M$506M1.7x
GartnerUnited StatesUnited StatesPublicly listed$6.5B$1.2B$12B2.1x

Precision Medicine Group Public Comps

Precision Medicine Group is no longer listed, but its public comps include Huron Consulting Group, TIC Solutions, Alten, Ipsos, ICF International, CBIZ, Maximus, SMS, Everforth and Clarivate.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Huron Consulting Group$1.7B$202M2.0x1.8x16.5x12.6x
TIC Solutions$1.5B$168M2.2x1.6x19.7x10.6x
Alten$4.7B$344M0.6x0.5x7.6x5.2x
Ipsos$2.9B$429M0.7x0.7x4.8x4.5x
ICF International$1.9B$201M1.1x1.1x10.5x10.0x
CBIZ$2.8B$366M1.8x1.7x13.2x10.4x
Maximus$5.4B$663M0.9x0.9x7.0x-
SMS$416M($63M)3.3x3.2x(21.9x)19.9x

This data is available for Pro users. Sign up to see all Precision Medicine Group competitors and their valuation data.

Start Free Trial

Common questions about Precision Medicine Group

When was Precision Medicine Group founded?Precision Medicine Group was founded in 2012.
Where is Precision Medicine Group headquartered?Precision Medicine Group is headquartered in Washington, DC, United States.
Is Precision Medicine Group publicly listed?No, Precision Medicine Group was acquired by McKesson in August 2026.
Who acquired Precision Medicine Group?Precision Medicine Group was acquired by McKesson in August 2026.
How much was Precision Medicine Group acquired for?Precision Medicine Group was acquired for $2.3B in August 2026, a 2.4x revenue multiple.
How much funding has Precision Medicine Group raised?Precision Medicine Group has raised $310M across 2 funding rounds.
What was Precision Medicine Group's last funding round?Precision Medicine Group's last funding round was a $35M undisclosed-stage round in March 2021.
Who are Precision Medicine Group's investors?Precision Medicine Group's investors include Berkshire Partners, J.H. Whitney & Co, TPG and Oak Investment Partners.
Which companies are comparable to Precision Medicine Group?Companies comparable to Precision Medicine Group include Ipsos, Mu Sigma, Clarivate, Sutherland, GlobalData and Gartner.
How many companies has Precision Medicine Group acquired?Precision Medicine Group has acquired 3 companies, including Project Farma, Stern Investor Relations and Epiontis.

See companies similar to Precision Medicine Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial